Metastatic Malignant Paraganglioma of Rare Sites Failed on Conventional Treatments Demonstrating Beneficial Response to ¹⁷⁷Lu-DOTATATE PRRT

Abstract

The incidence of paraganglioma (PGL) is rising due to better imaging modalities employed for evaluating incidentaloma and surveillance of the asymptomatic carriers. Benign and malignant PGLs often cannot be reliably diagnosed on histology alone, and the documentation of metastases is important in the diagnosis of malignancy. Advancement in genomics has improved our understanding of PGL. ⁶⁸Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) scan shows a significant superior detection rate compared with other conventional functional and anatomical imaging modalities, can detect rare sites of primary disease in PGL, and also aids in patient selection for peptide receptor radionuclide therapy (PRRT). PRRT is increasingly used in metastatic setting with good symptomatic and biochemical response and disease stabilization in metastatic PGL patients. We present a series of three patients with PGLs located in rare primary sites (sigmoid colon, urinary bladder, and carotid body space), which showed recurrence of disease on conventional treatments and developed metastatic disease in the lymph nodes, liver, skeleton, and lungs. PRRT with ¹⁷⁷Lu-DOTATATE achieved symptom control, favorable biochemical and imaging responses, and increased progression-free and overall survival rate in the described patients.

Keywords

paraganglioma - metastatic PGL - ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy - ⁶⁸Ga-DOTATATE PET-CT scan - sigmoid colon PGL - urinary bladder PGL

Publikationsverlauf

Artikel online veröffentlicht:
25. Oktober 2024

• References

• 1 Lenders JWM, Kerstens MN, Amar L. et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020; 38 (08) 1443-1456
• 2 Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015; 11 (02) 101-111
• 3 Lenders JW, Pacak K, Walther MM. et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 2002; 287 (11) 1427-1434
• 4 Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 2017; 28 (03) 213-227
• 5 Jochmanova I, Wolf KI, King KS. et al. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol 2017; 143 (08) 1421-1435
• 6 van Nederveen FH, Gaal J, Favier J. et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009; 10 (08) 764-771
• 7 Papathomas TG, Oudijk L, Persu A. et al. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol 2015; 28 (06) 807-821
• 8 Snezhkina AV, Kalinin DV, Pavlov VS. et al. Immunohistochemistry and mutation analysis of SDHx genes in carotid paragangliomas. Int J Mol Sci 2020; 21 (18) 6950
• 9 Selak MA, Armour SM, MacKenzie ED. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7 (01) 77-85
• 10 Letouzé E, Martinelli C, Loriot C. et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23 (06) 739-752
• 11 Neumann HP, Pawlu C, Peczkowska M. et al; European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292 (08) 943-951
• 12 Janssen I, Blanchet EM, Adams K. et al. Superiority of [⁶⁸Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015; 21 (17) 3888-3895
• 13 Tampakis A, Schlageter M, Oertli D, Misteli H. Letter to the editor: a case of an extraadrenal paraganglioma in the sigma in a patient with recurrent sigmadiverticulitis. Int J Colorectal Dis 2016; 31 (03) 729-731
• 14 Kimura N, Takayanagi R, Takizawa N. et al; Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2014; 21 (03) 405-414
• 15 Hamidi O, Young Jr WF, Iñiguez-Ariza NM. et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 2017; 102 (09) 3296-3305
• 16 Leestma JE, Price Jr EB. Paraganglioma of the urinary bladder. Cancer 1971; 28 (04) 1063-1073
• 17 Withey SJ, Christodoulou D, Prezzi D. et al. Bladder paragangliomas: a pictorial review. Abdom Radiol (NY) 2022; 47 (04) 1414-1424
• 18 Li M, Xu X, Bechmann N. et al. Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. World J Urol 2022; 40 (02) 385-390
• 19 Yu K, Ebbehøj AL, Obeid H. et al. Presentation, management, and outcomes of urinary bladder paraganglioma: results from a multicenter study. J Clin Endocrinol Metab 2022; 107 (10) 2811-2821
• 20 Ko A, Ezzeldin O, Bezold S, Bhargava P. Metastatic urinary bladder paraganglioma on Ga-68 DOTATATE PET/CT. Radiol Case Rep 2021; 16 (09) 2763-2767
• 21 Lee JH, Barich F, Karnell LH. et al; American College of Surgeons Commission on Cancer, American Cancer Society. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 2002; 94 (03) 730-737
• 22 Gu G, Wang Y, Liu B. et al. Distinct features of malignant carotid body tumors and surgical techniques for challengeable lesions: a case series of 11 patients. Eur Arch Otorhinolaryngol 2020; 277 (03) 853-861
• 23 Shamblin WR, ReMine WH, Sheps SG, Harrison Jr EG. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg 1971; 122 (06) 732-739
• 24 Janssen I, Chen CC, Taieb D. et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med 2016; 57 (02) 186-191
• 25 Averbuch SD, Steakley CS, Young RC. et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109 (04) 267-273
• 26 Hadoux J, Favier J, Scoazec JY. et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014; 135 (11) 2711-2720
• 27 Jaiswal SK, Sarathi V, Memon SS. et al. 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma. Endocr Connect 2020; 9 (09) 864-873
• 28 Lin F, Carrasquillo JA, Rivero JD. et al. Safety and efficacy of Lu-177-DOTATATE in metastatic or inoperable pheochromocytoma/paraganglioma: an interim analysis. J Nucl Med 2023; 64: 1296
• 29 Parghane RV, Talole S, Basu S. ¹³¹I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy. Ann Nucl Med 2021; 35 (01) 92-101
• 30 Parghane RV, Ostwal V, Ramaswamy A. et al. Long-term outcome of “sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging 2021; 48 (03) 913-923